Inhibition of fatty acid amidohydrolase (FAAH), the enzyme responsible for the selective in vivo degradation of the endocannabinoid anandamide, elicits CB1 receptor-mediated anxiolytic, analgesic and cardiovascular depressor effects, without inducing behavioral effects predictive of addictive potential. We have recently demonstrated that a novel, highly potent, in vivo effective FAAH inhibitor, AM3506, normalizes the elevated blood pressure and inappropriately increased cardiac contractility of both anesthetized and conscious spontaneously hypertensive rats (SHR) without affecting these parameters in normotensive animals. The cardiovascular depressor effects in SHR were maintained following ganglionic blockade and restoration of blood pressure by vasopressin infusion, and thus could be attributed to a reduction in sympathetic tone elicited via activation of CB1 receptors in the central nervous system by endogenous anandamide. We further showed that the greater sensitivity of hypertensive relative to normotensive animals to CB1R-mediated cardiovascular depressor effects is related to increased efficiency of coupling of CB1R to G proteins. These findings suggest that targeting the endocannabinoid system may have therapeutic value in hypertension. Additionally, we have found that AM3506 does not induce metabolic side effects including hyperglycemia/glucose intolerance. Such effects are commonly seen with other FAAH inhibitors, such as URB597, or in FAAH-/- mice, and are due to inhibition of FAH in the liver and the consequent increase in hepatic anndamide levels that result in activation of hepatic CB1 receptors. We have demonstrated that the the unique lack of such side effects with AM3506 is due to its very rapid metablism by the liver, resulting in ts inabiliity to block FAAH in the liver. These results are in press at Chemistry &Biology.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2010
Total Cost
$454,560
Indirect Cost
Name
National Institute on Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
Zip Code
Pacher, Pal; Steffens, Sabine; Haskó, György et al. (2018) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 15:151-166
Valenta, Ines; Varga, Zoltan V; Valentine, Heather et al. (2018) Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach. JACC Cardiovasc Imaging 11:320-332
Gunduz-Cinar, Ozge; Flynn, Shaun; Brockway, Emma et al. (2016) Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids. Neuropsychopharmacology 41:1598-609
Gaskari, Seyed Ali; Liu, Hongqun; D'Mello, Charlotte et al. (2015) Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol 62:1272-7
Kunos, George; Volkow, Nora D (2013) Preface to the special issue of psychopharmacology: 10ýýyears of the Jacob P. Waletzky Award. Psychopharmacology (Berl) 229:383-4
DePoy, Lauren; Daut, Rachel; Brigman, Jonathan L et al. (2013) Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc Natl Acad Sci U S A 110:14783-8
Gunduz-Cinar, O; MacPherson, K P; Cinar, R et al. (2013) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18:813-23
Bashashati, M; Storr, M A; Nikas, S P et al. (2012) Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol 165:1556-71
Engeli, Stefan; Bluher, Matthias; Jumpertz, Reiner et al. (2012) Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens 30:2345-51
Heilig, Markus; Warren, Kenneth R; Kunos, George et al. (2011) Addiction research centres and the nurturing of creativity: the National Institute on Alcohol Abuse and Alcoholism. Addiction 106:1052-60

Showing the most recent 10 out of 18 publications